
The moderator asks one of the panelists to compare the DASL-HiCaP trial with the STAMPEDE and ENZARAD trials.

The moderator asks one of the panelists to compare the DASL-HiCaP trial with the STAMPEDE and ENZARAD trials.

The panel opens by defining high-risk localized prostate cancer. One panelist looks at Gleason grade, T stage, spread to the seminal vesicles or lymph nodes, and PSA level.